Echelon Biosciences, Lumiphore In Licensing Agreement

Salt Lake City, Utah-based Echelon Biosciences said this week that it has finalized a license agreement with Lumiphore to use its technology for the development of cancer assays. Echelon said that it would have access to Lumiphore's lanthanide-complex technology, used for research and drug discovery. The technology is useful in new drug development for cancer, diabetes, and inflammation. Financial terms were not disclosed.